Intravenous immunoglobulin: regulatory perspectives on use and supply
Authors:
- 1 April 2001
- journal article
- review article
- Published by Wiley in Transfusion Medicine
- Vol. 11 (2) , 63-74
Abstract
Technological advancements in the fractionation of plasma in the early 1970s led to the production of immunoglobulin preparations which could be administered intravenously. The ability to deliver larger doses than was possible with intramuscular products was accompanied by clinical studies demonstrating the efficacy of immunoglobulin treatment in a number of autoimmune and inflammatory conditions. This has led to a continuing increase in the usage of this product such that, currently, it is considered to be the driving force for plasma procurement. In recent years, difficulties have been experienced in the supply of this product in various markets.While intravenous immunoglobulins (IVIG) have undoubted clinical superiority over intramuscular products for the majority of indications, their use should be tempered with caution. Early clinical studies revealed that the risk of viral transmission from these products was higher than that of the traditional intramuscular presentation. This has had a profound impact on blood transfusion science as it has provided a major impetus for nucleic acid testing (NAT) for viral agents in blood donations. Perhaps less widely appreciated are the pressures which may be felt in blood services as the traditional drivers for plasma procurement – factor VIII and albumin – become secondary to IVIG. This review discusses the factors affecting the supply and safety of IVIG and the implications of recent global regulatory decisions on the delivery of this product and other therapeutic products derived from human plasma.Keywords
This publication has 53 references indexed in Scilit:
- Monocyte–macrophage system as targets for immunomodulation by intravenous immunoglobulinBlood Reviews, 2000
- Adverse Effects of Intravenous Immunoglobulin TherapyDrug Safety, 1999
- Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations1995
- Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsThe Lancet, 1995
- Inactivation of Hepatitis C Virus in Low pH Intravenous ImmunoglobulinBiologicals, 1994
- Long-term persistence of hepatitis C virus antibodies in a single source outbreakJournal of Hepatology, 1991
- Development of Immunoglobulin Preparations for Intravenous UseVox Sanguinis, 1986
- Preparation of a Stable Intravenous Gamma‐Globulin: Process Design and Scale‐UpVox Sanguinis, 1980
- Development of an Intravenous γ‐Globulin with Fc ActivitiesVox Sanguinis, 1977
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946